Chengdu, August 2025 — Zennova (诺峰药业) announced a strategic collaboration with Rapafusyn Pharmaceuticals, a U.S.-based biotech company, to jointly advance the development of innovative non-degrading molecular glue medicines. This partnership aims  at leveraging Zennova’s proprietary BioCarier® technology platform to help speed up the development of Rapafusyn’s RapaGlue™ drug candidates, including RAP-8020 and other pipeline assets.

Rapafusyn Pharmaceuticals, co-founded by Prof. Jun Liu of Johns Hopkins University, is pioneering the RapaGlue™ platform to target historically ‘undruggable’ proteins such as transcription factors, transmembrane proteins, and protein–protein interactions (PPI). The collaboration with Zennova combines Rapafusyn’s novel molecular glue modality with BioCarier®’s unique drug delivery capabilities, with the goal to develop breakthrough drugs formulations that can potentially be generally applicable to RapaGlue™ drug candidates in oncology, immunology, kidney diseases and pain.

BioCarier®is an innovative, patent-protected delivery system designed to further enhance oral bioavailability for Biopharmaceutics Classification System (BCS) IV molecules and large molecules over 1,000 Da. It demonstrates superior encapsulation efficiency (>90% for RapaGlue™-like compounds) and enhances cellular uptake by 5–10 times compared to traditional methods. Preclinical results confirm BioCarier®’s ability to improve oral bioavailability and even facilitate blood–brain barrier penetration, setting a new benchmark for drug delivery technologies.

Dr. Sean Hu, President and CEO of Rapafusyn, said: “The integration of Zennova’s BioCarier® technology with our RapaGlue™ platform could potentially lead to formulation solutions that can be applied broadly to Rapafusyn’s rapidly growing pipeline of RapaGlue drug candidates and significantly accelerate their paths to the clinic.

Dr. Dahai Guo, Founder and CEO of Zennova, stated: “This collaboration not only validates the value of our BioCarier® platform but also extends its application to the development of the cutting-edge non-degrading molecular glue modality-based medicines”

About Rapafusyn Pharmaceuticals

Rapafusyn Pharmaceuticals is a biotechnology company dedicated to developing RapaGlue™, a novel class of non-degrading molecular glues designed to effectively modulate previously undruggable targets including transcription factors, transmembrane proteins, and protein-protein interaction disease targets.  Rapafusyn has leveraged its proprietary large DNA-encoded libraries (DELs) of rationally designed FKBP12 binding macrocyclic peptides (RapaGlues™) and assembled a diverse pipeline of potential first-in-class or highly differentiated best-in-class programs directed at high-value immunology, oncology, pain and renal diseases.

About BioCarier®

BioCarier® is a next-generation drug delivery technology developed by Zennova to enhance solubility, absorption, and bioavailability of difficult-to-formulate compounds. It reduces food effects, minimizes drug–drug interactions, and has demonstrated the ability to cross the blood–brain barrier. By enabling efficient delivery of both small molecules and large biomolecules, BioCarier®sets a new global standard in drug delivery innovation. Through this unique combination of features, BioCarier® not only enhances the performance of existing molecules but also enables drug developers to explore new therapeutic frontiers previously limited by delivery challenges.